Kornimate/medical-research-clean huggingface dataset:
maternal positioning and occipitoposterior fetal position

Conditions: Maternal Distress in Labor; Persistent Occipitoposterior or Occipitoanterior Position; Dystocia; Fetal Position and Presentation Abnormalities

Summary: the aim of the study is to evaluate the efficacy of a specific maternal position to correct fetal position in occipito-posterior during the labor. the investigators hypothesize that the maternal position described by the dr de gasquet facilitate the rotation in occipito-anterior during the labor. the calculated sample size is 438 participants (219 in each group)

randomized clinical trial

Eligibility criteria:
inclusion criteria: * singleton * primiparous and multiparous * term ≥ 37 weeks * labor in dilatation phase (cervix effaced, permeable finger 2 to 9 cm) * diagnosis of occipitoposterior variety confirmed by ultrasound exclusion criteria: * maternal age below 18 years old * misunderstanding the french language * full dilatation of the cervix * posture evaluated already adopted by the woman during labor

Keywords: maternal position occipitoposterior position labor dystocia fetal presentation abnormalities
food supplement treatment for wasting children in indonesia

Conditions: Wasting; Nutrition Disorder, Child

Summary: assessing program efficacy of under five food supplementation (pmt biscuits) is needed after the first 6 months of exclusive breastfeeding, children were introduced to liquid and semi-solid food. in this phase of food introduction, children ability to accept food supplementation program was still questionable and the efficacy needs to be assessed. another aspect that needed to be evaluated is assessing the efficacy of food supplementation to improve the nutritional status of wasting children in multiple cities to describe indonesian geographical and socio-economic diversity (multi center studies). pmt biscuits supplementation intervention is accompanied by educational modules on infant and young child feeding (iycf) in order to improve caregiver's knowledge and skills in providing economically affordable and nutritious food for their children. pmt biscuits supplementation evaluation will be assessed at 9 months observations (3 months intervals). the observation will be conducted every month up until the first 3 months then the observation will be continued in 6th and 9th months of observation.


Eligibility criteria:
inclusion criteria: * age 6-17 months (still included in under two years old children during the intervention period) * underweight children by weight-per-height less than -2.00 * not received pmt biscuits at the time of recruitment * parents agree to follow the research exclusion criteria: * severe wasting (weight for height less than -3 z-score) * severe food insecurity households (severe household food insecurity) * tuberculosis infection based on anamnesis * the possibility of moving to another city within 6 months of intervention

Keywords: infant and young child feeding program evaluation food supplementation biscuit wasting children
a study to evaluate energi-f703 gel in venous leg ulcer

Conditions: Venous Leg Ulcer

Summary: this is a randomized, double-blind, placebo-controlled, phase ii, multi-centered study to evaluate the efficacy and safety of energi-f703 gel in subjects who are ≥ 20 years old with venous leg ulcer (vlu). subjects will be recruited from multiple sites in taiwan. the treatment period will be 84 days with another 84-day follow-up period.


Eligibility criteria:
inclusion criteria: 1. with either gender aged at least 20 years old 2. with venous reflux \>0.1 sec measured by duplex ultrasound imaging dated within 6 months prior to the screening visit 3. with at least one venous ulcer on the lower leg (knee to ankle inclusive) and not healing for at least 4 weeks. the ulcer with the largest surface area will be selected as target ulcer. if two or more ulcers have the largest size, the one with the longest duration will be selected 4. with the target ulcer size of 2 cm2 to 50 cm2 5. target vlu involves a full thickness skin loss, but without exposure of tendon, muscle, or bone 6. target vlu should be free of any necrosis or infection in any soft tissue and bone tissue 7. able to tolerate compression therapy 8. subject has signed the written informed consent form exclusion criteria: 1. target vlu with active cellulitis or osteomyelitis 2. with target ulcer size decreased by at least 30% after 2 weeks of standard care 3. with poor nutritional status (albumin \ 12%), a leukocyte counts \ 3 × upper limit of normal range) tests within 14 days prior to screening visit or 28 days prior to randomization visit 4. requiring treatment with chemotherapeutic agents 5. with known or suspected hypersensitivity to any ingredients of ip and matched vehicle 6. with coronary heart disease with myocardial infarction, coronary artery bypass graft (cabg), or percutaneous transluminal coronary angioplasty (ptca) within 3 months prior to screening visit 7. (1) female subject of childbearing potential who: * is lactating; or * has positive pregnancy test result at eligibility checking; or * refuses to adopt at least one form of birth control from signing informed consent to the end of study note: acceptable forms include: established use of oral, injected or implanted hormonal methods of contraception. placement of an intrauterine device (iud) or intrauterine system (ius).barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) 7(2) male subject with female spouse/partners who are of childbearing potential refuses to adopt at least one form of birth control (at least one of which must be a barrier method) from signing informed consent to the end of study) 8. with ankle brachial index (abi) \< 0.6 9. enrollment in any investigational drug trial within 4 weeks before entering this study 10. with any condition judged by the investigator that entering the trial may be detrimental to the subject
phase i trial of dar-901

Conditions: Tuberculosis

Summary: this is a phase 1, randomized, controlled, double-blind, multiple-dose, dose-ranging study of dar 901, (an inactivated whole cell mycobacterial vaccine) to be conducted in hiv negative and hiv positive adults previously vaccinated with bcg. the goals of the trial are to determine the safety, tolerability, and immunogenicity of multiple doses of the vaccine at different dose levels, ranging from 0.1 to 1 mg.


Eligibility criteria:
inclusion criteria: all subjects: age 18-65, prior bcg vaccine (scar) 56 hiv negative subjects: negative elisa for hiv (48 subjects with negative igra, 8 subjects with positive igra) 21 hiv positive subjects: positive elisa for hiv, on art (13 subjects with negative igra, 8 subjects with positive igra) exclusion criteria: pregnancy, positive serology for hepatitis b or c, active tuberculosis immunosuppression, severe medical illness -

Keywords: tuberculosis bcg hiv tb vaccines
differential acute tolerance development to effects of nitrous oxide - 7

Conditions: Opioid-Related Disorders; Substance-Related Disorders

Summary: the purpose of this study is to conduct experiments to examine subjective and reinforcing effects of nitrous oxide. mood altering and psychomotor effects will be tested on non-drug abusers and preference procedures will be used to assess reinforcing effects. to examine differential acute tolerance development to effects of nitrous oxide in humans.


Eligibility criteria:
please contact site for information.

Keywords: nitrous oxide acute tolerance subjective effects analgesia psychomotor healthy volunteer
assessing the impact of insti to pi switch on insulin sensitivity and fat metabolism

Conditions: HIV I Infection; Adiposity

Summary: a substudy of tmc114fd2htx4004 that will perform glucose tolerance testing, adipose testing and mri scan at baseline, 12 and 24 weeks post switch of art medications.

synopsis full study title: assessing the impact of integrase strand transfer inhibitors (insti) to protease inhibitor (pi) switch on insulin sensitivity and fat metabolism (adiposity): a sub-study of define endpoints and objectives: the following endpoints will be determined 12 and 24 weeks after switch from an insti-based antiretroviral therapy (art) regimen to a pi-based regimen: primary endpoint: change in insulin sensitivity (si) at 12 weeks assessed by using a 3-hour frequently sampled oral glucose tolerance testing (fsogtt). secondary endpoints: 1) change in insulin sensitivity (si) at 24 weeks assessed by using a 3-hour frequently sampled oral glucose tolerance testing (fsogtt); 2) change in insulin secretion during the fsogtt assessed by using c-peptide deconvolution; 3) change in intrahepatic triglyceride (ihtg) content measured by magnetic resonance imaging (mri); 4) change in adipocyte size by the osmium tetroxide fixation technique; and 5) change in expression of genes associated with adipose tissue development, lipogenesis, inflammation and endocrine function by rna sequencing. hypothesis: insulin sensitivity will improve following switch from instis to pis

Eligibility criteria:
inclusion criteria: * • must be enrolled in the define study tmc114fd2htx4004 * must sign an icf indicating that they understand the purpose of, and procedures required for, the study and are willing to participate in the study. exclusion criteria: * • contraindication to magnetic resonance imaging as determined by institutional policy. * current diagnosis of diabetes mellitus
percutaneous plug-based femoral arteriotomy closure device use in surgery for acute type a aortic disection

Conditions: Aortic Dissection

Summary: a single-center prospective study. patients undergoing surgery for acute type a aortic dissection with femoral arterial cannulation between 2017 and 2022 at the karolinska university hospital in stockholm, sweden are eligible. femoral cannulation was performed either with surgical cut-down and arterial puncture under direct vision or percutaneously with planned percutaneous arteriotomy closed using a plug-based arteriotomy closure device (manta, essential medical inc., malvern, pennsylvania). data regarding preoperative clinical characteristics and operative details were obtained by medical records review.


Eligibility criteria:
inclusion criteria: * operated for acute type a aortic dissection between 2017 and 2022 at the karolinska university hospital in stockholm, sweden. exclusion criteria: * non-femoral arterial cannulation * concomitant femoro-femoral bypass * conversion to ecmo with arterial inflow in the previously cannulated femoral artery * death within 30 days from procedure * loss to follow-up
ultrathin strut sirolimus-eluting stent with bioabsorbable polymer in patients receiving chronic oral anticoagulation

Conditions: Coronary Artery Disease; Ischemic Heart Disease

Summary: patients receiving chronic oral anticoagulation with indication for percutaneous coronary revascularization with stent implantation, and needing for antiplatelet therapy, are at high risk of bleeding. the new generation of ultrathin strut sirolimus-eluting stent with bioabsorbable polymer allow for shorter antiplatelets regimens and could be a good option for this high-bleeding risk patients.

patients receiving chronic oral anticoagulation with indication for percutaneous coronary revascularization with stent implantation, and needing for antiplatelet therapy, are at high risk of bleeding. the new generation of ultrathin strut sirolimus-eluting stent with bioabsorbable polymer allow for shorter antiplatelets regimens and could be a good option for this high-bleeding risk patients.

Eligibility criteria:
inclusion criteria: patients must meet all inclusion criteria: * patients with signed informed consent and * patients with \>=18 years old and * patients with chronically receiving oral anticoagulation treatment with any type of anticoagulant for any reason and * patients with de novo coronary artery disease requiring both elective or urgent percutaneous revascularization due to stable coronary artery disease or acute coronary syndrome with or without st-segment elevation, and in which an ultrathin strut sirolimus-eluting stent with bioabsorbable polymer has been used exclusion criteria: patients do not have to meet any exclusion criteria * patients treated percutaneously with any type of stent other than the supraflex cruz® in the 6 months prior to the index procedure in which he or she is included. * use in the same procedure or in a scheduled procedure of other stents different from the one evaluated for the treatment of another vessel(s). * patients treatment for restenosis or stent thrombosis. * patients presentation in cardiogenic shock or after cardiorespiratory arrest. * patients with allergy to any of the components of the stent to be used. * patients with impossibility for follow-up. * patients with life expectancy less than 1 year.

Keywords: chronic oral anticoagulation ultrathin-strut stent biodegradable polymer high-bleeding risk percutaneous coronary intervention
diabetes self-management plus tai chi easy

Conditions: Type 2 Diabetes Mellitus

Summary: the purpose of this project is to increase access to diabetes care and education for adults aged 40-64 years old who are diagnosed with type 2 diabetes mellitus and are unable to attend education and support classes due to their work situation. this project will use an established, well-known program for diabetes self-management education and support (dsmes) and combine it with tai chi easy (tce)™ to enhance physical health, psychological health, and health behaviors. participants will be asked to attend 45 minutes of dsmes and 45 min of tce twice a week for 6 weeks. all classes will be recorded and available online and can viewed at a time when it is most convenient to accommodate working adults. participants will be asked to complete survey questionnaires online, at the beginning and end of the program; and have a smart phone to connect with a smart ring during the 6-week dsmes+tce program. after the program is done, participants will be asked to return the smart ring. upon receipt of the smart ring, they will receive a give a gift card to thank them for their participation in the program.


Eligibility criteria:
inclusion criteria: * diagnosed with t2dm * any sex/gender * any race/ethnicity * any socioeconomic group * has a smartphone * receives care in a federally qualified healthcare center in southern arizona exclusion criteria: * individuals with t1dm * individuals with gestational dm * individuals with pre-diabetes * children * pregnant women * individuals unable to provide informed consent * individuals with other serious co-occurring health condition (e.g., active cancer treatment)

Keywords: diabetes self-management tai chi
collection of blood for multiple collaborative studies

Conditions: HIV

Summary: this study seeks to confidentially collect blood from hiv-positive individuals and hiv-negative controls to provide basic scientists with specimens for collaborative studies.

hiv positive patients are currently the focus of multiple collaborative research studies, both at ucsf and other institutions. the aims of these research projects include improving the understanding of etiology, immunology, epidemiology and treatment of hiv. there are numerous requests from basic scientists at ucsf for collaborative studies on specimens, especially for blood, saliva and urine samples. specimens may be used to test such things as virus characteristics, genotyping and/or phenotyping resistance, plasma drug concentrations, immune function or evidence of complications of hiv disease. the samples may also be tested for genetic factors that may be related to the course of hiv disease

Eligibility criteria:
inclusion criteria: * hiv-1 antibody negative with similar characteristics to hiv-1 positive cohort * hiv-positive subjects naive to antiretroviral therapy * hiv-positive subjects stable on or off antiretroviral therapy for a minimum of 6 months * good venous access * able to provide informed consent exclusion criteria: * hemoglobin \< 9g/dl * hematocrit \< 27% * active treatment for cancer * hospitalization or iv antibiotic use within the last 4 months * immunosuppressive therapy within the last 4 months

Keywords: hiv observational pathogenesis immunology virology control healthy control men who have sex with men
evaluation of the effectiveness and tolerance of tetracosactide synacthen® in the treatment of post dural puncture headaches (esybreche)

Conditions: Post-dural Puncture Headache

Summary: the aim of the study is to assess the efficacy and safety of synacthène® versus placebo in the treatment of post-dural puncture syndrome in patients receiving epidural analgesia, spinal analgesia, or combined spinal-epidural analgesia for labour.


Eligibility criteria:
inclusion criteria: all women who received epidural, spinal, or combined spinal-epidural labour analgesia and presenting post-dural puncture headache: * intense: with ≥3 / 10 numerical rating pain scale * appearing within 5 days after delivery * aggravating in sitting or standing position and / or improving supine * can be associated with one of the following criteria: tinnitus, nausea, photophobia, neck stiffness or pain, hearing loss * after exclusion of clinically differential diagnoses (preeclampsia or eclampsia, cerebral venous thrombosis, migraine) * age greater than or equal to 18 years * affiliation to social security scheme * inform consent signed after oral and written information exclusion criteria: * presence of diplopia (indication of immediate blood patch) * contraindication to acth or synacthène® (unbalanced hypertension, uncontrolled diabetes, uncontrolled psychosis, infectious viral disease state or evolving) * processing of torsade de pointe provider (astenizole, bepridil, erythromycin iv, halofantrine, pentamidine, sparfloxacin, sultopride, terfenadine, vincamine) * live vaccine in the months prior to inclusion * hypersensitivity to synacthène® * patient who have previously received synacthène® after delivery * contraindication to blood patch (fever or leukocytosis, hiv or hcv patient) * eclampsia or preeclampsia during this pregnancy * patient who have received prophylactic blood patch (at diagnosis of accidental dural puncture) * minor under 18 or protected * psychological disorders do not allowing informed consent * refusal of participation in the study or participation in another ongoing interventional study * withdrawal of consent

Keywords: tetracosactide synacthène® cosyntropin post-dural syndrom post-dural puncture headache
abrocitinib expanded access protocol in adolescents and adults with moderate to severe atopic dermatitis

Conditions: Atopic Dermatitis

Summary: this is a multi-center, expanded access protocol to provide access to the investigational product, abrocitinib, to adolescent and adult patients with moderate to severe atopic dermatitis who have inadequate treatment options with available and approved medicated topical and systemic therapies and who are otherwise ineligible for participation in clinical studies with abrocitinib.

this is a multi-center expanded access protocol (eap) for the treatment of up to approximately 500 adult and adolescent (defined as age \< 18 years) patients with moderate to severe atopic dermatitis for whom standard, approved medicated topical and systemic treatment options are inadequate and who would be suitable candidates for a trial of abrocitinib for potential treatment of moderate to severe atopic dermatitis. the study will also collect safety and exploratory efficacy data. participants who meet the inclusion criteria and none of the exclusion criteria may be enrolled into the eap to receive open-label oral treatment with abrocitinib.

Eligibility criteria:
inclusion criteria: * 12 years of age or older * clinical diagnosis of chronic atopic dermatitis for at least 6 months * inadequate treatment options with available, approved medicated topical and systemic therapies for moderate to severe atopic dermatitis * moderate to severe atopic dermatitis as indicated by at least one of the following: iga ≥3; easi ≥16 * not eligible for participation in any ongoing clinical trial of abrocitinib, including lack of access due to geographical limitations exclusion criteria: * medical, psychiatric, or laboratory abnormality that may increase the risk associated with study participation * medical history including thrombocytopenia, coagulopathy or platelet dysfunction, malignancies, current or history of certain infections, lymphoproliferative disorders and other medical conditions at the discretion of the investigator * require treatment with prohibited medications during the study * discontinued prior treatment with any systemic jak inhibitor due to safety or tolerability issues * 12 to \<18 years old without documented evidence of having received at least one dose of the varicella vaccine or without evidence of prior exposure to varicella zoster virus based on serological test * pregnant or breastfeeding women or women of childbearing potential who are sexually active and unwilling to use contraception

Keywords: atopic dermatitis eczema expanded access
chemotherapy resistance and sensitivity testing in lung tumors

Conditions: Lung Cancer

Summary: the purpose of this study is to screen chemotherapy drugs currently used to treat lung cancer and determine the most effective treatment based on results of chemo sensitivity testing on the patients own cancer cells in the laboratory. the results of this screening will not influence the patients treatment.

the chemosensitivity assay will be performed on tissue obtained during the diagnostic fine needle aspiration, core biopsy, or excisional biopsy of the lung lesion. cancer cells (bulk of tumor) and cancer stem cells (cscs) will be isolated and expanded in the laboratory. the drug screening assay will be used to evaluate the response of the cscs and of the cancer cells to the various chemotherapy regimens.

Eligibility criteria:
inclusion criteria: * suspected or confirmed diagnosis of lung cancer * undergoing a fine needle aspiration, core biopsy, or excisional biopsy for diagnosis. * chemotherapy must be clinically indicated for treatment of the patient's qualifying disease * patient must be at least 18 years of age * patient must have signed an irb approved informed consent form for the data collection study prior to entry of data into the enrollment form in the database. exclusion criteria: * patient pathology shows benign pathology for sample submitted * patient is not indicated to receive chemotherapy for their disease

Keywords: lung cancer chemosensitivity
biologics for stricturing crohn's diseases

Conditions: The Efficacy of Biologics for Stricturing Crohn's Diseases

Summary: recent researches have reported that biologics might be also effective for stricturing cd. however, the data were largely retrospective. prospective studied are needed for evaluate the efficacy of biologics for stricturing crohn's diseases.


Eligibility criteria:
inclusion criteria: * patients with stricturing crohn's diseases * no surgical indication * patients with asymptomatic penetrating diseases * written consent acquired exclusion criteria: * patients with surgical indication * patients with symptomatic penetrating diseases * contraindication of biologics * anticipating other trial